Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Thoracic 2Other solid neoplasm 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Advanced Solid Tumor 6Solid Tumors 3Solid Tumor 3Mesothelioma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumor, Adult 2Melanoma 2Cholangiocarcinoma 2Advanced Solid Tumors 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Refractory or Recurrent Solid Tumor 1Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Locally Advanced or Metastatic Solid Tumors 1Kidney Neoplasms 1Esophageal Neoplasms 1DMMR Colorectal Cancer 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Thiotepa 3Filgrastim 3sargramostim 2pembrolizumab 2belinostat 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Cyclophosphamide 2Busulfan 2tocilizumab 1spartalizumab 1atezolizumab 1Topotecan 1Stem Cell Transplantation 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Quality of Life 1Plicamycin 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Mesna 1Ipilimumab 1Interferon-gamma 1Interferon-alpha 1Immunotherapy 1Ifosfamide 1Fluorouracil 1FANG vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Kidney Neoplasms × spartalizumab × Other solid neoplasm × Clear all
NCT02460224 2022-02-10

Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1/2 Completed
490 enrolled 77 charts
DermatologicGenitourinaryOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Melanoma, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡